Clinical Trials

Dermira’s acne drug fails in two phase 3 trials

Dermira said that two phase 3 clinical trials testing its acne drug, olumacostat glasaretil, failed to meet their co-primary endpoints.

Emergent, Valneva begin phase 1 trial of Zika vaccine candidate

Emergent BioSolutions and Valneva have commenced a phase 1 clinical trial in the US to evaluate the safety and immunogenicity of their vaccine candidate VLA1601, against Zika virus.

Orano Med, RadioMedix recruit first patients in AlphaMedix phase 1 clinical trial

Orano Med and RadioMedix have recruited first three patients in the AlphaMedix phase 1 clinical trial.

BerGenBio completes recruitment into first stage of phase II breast cancer trial

BerGenBio has completed enrolment of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a potential new treatment regimen for advanced breast cancer.

Lilly’s Taltz yields positive results in phase 3 genital psoriasis trial

Eli Lilly and Company reported that Taltz (ixekizumab) in a phase 3b trial has helped patients with moderate-to-severe genital psoriasis in significantly reducing the impact of their condition on sexual activity.

Lilly’s radiographic axial spondyloarthritis treatment Taltz succeeds in phase 3 study

Eli Lilly announced that Taltz (ixekizumab) has met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (axSpA).

Diurnal Group completes patient enrolment in Chronocort’s trial for congenital adrenal hyperplasia

Diurnal Group has completed patient enrolment in its European pivotal Phase III clinical trial of Chronocort (modified release hydrocortisone) for the treatment of congenital adrenal hyperplasia (CAH) in adults.

Apalutamide delays spread of several prostate cancers in phase 3 trial

A group of investigators have demonstrated in a phase 3 clinical trial that apalutamide, an inhibitor of androgen receptor, delays spread of certain prostate cancers that had become resistant to standard androgen-deprivation therapy.

AstraZeneca’s Brilinta shows benefits for heart attack patients in phase III trial

AstraZeneca’s Brilinta significantly reduced cardiovascular (CV) events and coronary death beyond one year in heart attack survivors with multi-vessel disease in a Phase III trial.